Quote this publication Share Print

AVASTIN (bevacizumab), monoclonal antibody - RENAL CELL CARCINOMA

ONCOLOGY - Focus
Opinions on drugs - Posted on Jun 27 2016

Reason for request

Re-assessment of the improvement in actual benefit

Significant clinical interest without demonstrated clinical benefit in combination with interferon in the first-line management of advanced and/or metastatic renal cell carcinoma, in the absence of data versus clinically relevant comparators (sunitinib and pazotinib)

 

  • In renal cell carcinoma, AVASTIN has marketing authorisation in combination with interferon alpha-2a, in the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma. 
  • The addition of bevacizumab to interferon improves progression-free survival by 4.8 months relative to interferon alone. No conclusion on the contribution of AVASTIN to overall survival is possible.
  • New comparative efficacy data versus interferon alone, which is no longer a standard strategy, do not allow quantifying its contribution in this indication.
  • In combination with interferon, it is a treatment option in the first-line management of advanced and/or metastatic renal cell carcinoma with a good or intermediate prognosis.

 


Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Contact Us

Évaluation des médicaments